Loading
Crossbow Therapeutics makes antibody medicines that recognise fragments of proteins from inside cancer cells and pull the immune system's T cells onto them. Its first medicine is being tested in leukaemias and related blood cancers.
Crossbow Therapeutics, Inc., based in Cambridge, Massachusetts, develops T-cell receptor mimetic (TCRm) antibodies that bind tumour peptides presented on HLA, built into T-cell engagers it calls T-Bolt molecules. It was founded, seeded and incubated at MPM BioImpact. The lead programme CBX-250 targets a cathepsin G peptide presented by HLA-A*02:01 and is in the CROSSCHECK-001 phase 1 trial (NCT06994676) in relapsed or refractory AML, higher-risk MDS, CMML and CML, given under the skin; the company dosed its first patient in September 2025. A second programme, CBX-663, targets a TERT-derived peptide on HLA-A*02:01 and entered a phase 1 trial (NCT07779798) in myeloid malignancies, advanced solid tumours and recurrent glioblastoma, with a first patient dosed in September 2026. The company launched in July 2023 with an 80 million US dollar Series A led by MPM BioImpact and Pfizer Ventures, and raised a 77 million US dollar Series B in March 2026 co-led by Taiho Ventures and Arkin Bio Capital. Its first registered cancer trial, NCT06994676, was posted on ClinicalTrials.gov in May 2025.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Co-led by Taiho Ventures and Arkin Bio Capital | 2026 | $77M | crossbowtx.com |
| Series A · Led by MPM BioImpact and Pfizer Ventures, with Polaris Partners, BVF Partners, Eli Lilly and Company and Mirae Asset | 2023 | $80M | crossbowtx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Chronic myeloid leukaemia (CML), Acute myeloid leukaemia.
Shares Higher-risk myelodysplastic syndromes, T-cell engagers (bispecific), Acute myeloid leukaemia.
Shares Higher-risk myelodysplastic syndromes, Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Acute myeloid leukaemia.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Chronic myeloid leukaemia (CML), Acute myeloid leukaemia.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/